| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg |
| Targets |
11-Hydroxyrankinidine targets phosphodiesterase enzymes. Inhibition of phosphodiesterases can lead to increased intracellular levels of cAMP and cGMP, which are involved in various signaling pathways. The specific phosphodiesterase isoform targeted has not been fully characterized in the available literature.
|
|---|---|
| ln Vitro |
In vitro, 11-Hydroxyrankinidine has been shown to have bioactive properties. The compound is an alkaloid isolated from Gelsemium elegans. Detailed in vitro activity data, including specific enzyme inhibition assays and cell-based studies, are limited in the available literature.
|
| ln Vivo |
In vivo data for 11-Hydroxyrankinidine are limited in the available literature. The compound is a natural product isolated from Gelsemium elegans. Further in vivo studies are needed to evaluate its pharmacological effects and therapeutic potential.
|
| Enzyme Assay |
The compound's mechanism of action involves inhibition of phosphodiesterase enzymes. Detailed receptor-binding or enzyme inhibition studies have not been extensively reported in the available literature. The specific phosphodiesterase isoform and inhibition kinetics remain to be characterized.
|
| Cell Assay |
In vitro cell experiments using 11-Hydroxyrankinidine typically involve treating cells with the compound and assessing its effects on cell function and signal transduction. The compound's effects on phosphodiesterase activity and downstream signaling pathways can be measured.
|
| Animal Protocol |
In vivo animal studies using 11-Hydroxyrankinidine have not been extensively reported in the available literature. The compound is a natural product from Gelsemium elegans. Further studies are needed to evaluate its in vivo pharmacological effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 11-Hydroxyrankinidine are not available in the searched literature. As a natural product, its absorption, distribution, metabolism, and excretion properties have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for 11-Hydroxyrankinidine are limited. Gelsemium elegans is known to contain toxic alkaloids. The compound should be handled with appropriate safety precautions. As a research compound, it is intended for laboratory use only and not for human consumption.
|
| References | |
| Additional Infomation |
11-Hydroxyrankinidine has a molecular formula of C₂₀H₂₄N₂O₄ and a molecular weight of 356.42. It is an alkaloid compound isolated from Gelsemium elegans. The compound has been shown to have bioactive properties, which may be due to its ability to inhibit phosphodiesterase.
|
| Molecular Formula |
C20H24N2O4
|
|---|---|
| Molecular Weight |
356.41556
|
| Exact Mass |
356.173
|
| CAS # |
122590-03-8
|
| PubChem CID |
5318332
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
550.8±60.0 °C at 760 mmHg
|
| Flash Point |
286.9±32.9 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.658
|
| LogP |
1.99
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
26
|
| Complexity |
637
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CON1C(=O)C2(CC3NC\C(=C/C)C4CC2OCC34)c2ccc(O)cc12
|
| InChi Key |
FALAMCOLIJTCTR-QDEBKDIKSA-N
|
| InChi Code |
InChI=1S/C20H24N2O4/c1-3-11-9-21-16-8-20(18-7-13(11)14(16)10-26-18)15-5-4-12(23)6-17(15)22(25-2)19(20)24/h3-6,13-14,16,18,21,23H,7-10H2,1-2H3/b11-3+
|
| Chemical Name |
(7Z)-7-ethylidene-6'-hydroxy-1'-methoxyspiro[11-oxa-5-azatricyclo[6.3.1.04,9]dodecane-2,3'-indole]-2'-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8057 mL | 14.0284 mL | 28.0568 mL | |
| 5 mM | 0.5611 mL | 2.8057 mL | 5.6114 mL | |
| 10 mM | 0.2806 mL | 1.4028 mL | 2.8057 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
